Yüklüyor......
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
The introduction of checkpoint inhibitors provided remarkable achievements in several solid tumors but only 5% of metastatic colorectal cancer (mCRC) patients, i.e., those with bearing microsatellite instable (MSI-high)/deficient DNA mismatch repair (dMMR) tumors, benefit from this approach. The fav...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7465130/ https://ncbi.nlm.nih.gov/pubmed/32824490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082317 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|